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Abstract
Background:  Rheumatoid arthritis (RA) is characterized by chronic poly-arthritis, synovial
hyperplasia, erosive synovitis, progressive cartilage and bone destruction accompanied by a loss of
body cell mass. This loss of cell mass, known as rheumatoid cachexia, predominates in the skeletal
muscle and can in part be explained by a decreased physical activity. The murine collagen induced
arthritis (CIA) model has been proven to be a useful model in RA research since it shares many
immunological and pathological features with human RA. The present study explored the
interactions between arthritis development, locomotion and muscle mass in the CIA model.
Methods: CIA was induced in male DBA/1 mice. Locomotion was registered at different time
points by a camera and evaluated by a computerized tracing system. Arthritis severity was detected
by the traditionally used semi-quantitative clinical scores. The muscle mass of the hind-legs was
detected at the end of the study by weighing. A methotrexate (MTX) intervention group was
included to study the applicability of the locomotion and muscle mass for testing effectiveness of
interventions in more detail.
Results: There is a strong correlation between clinical arthritis and locomotion. The correlations
between muscle mass and locomotion or clinical arthritis were less pronounced. MTX intervention
resulted in an improvement of disease severity accompanied by an increase in locomotion and
muscle mass.
Conclusion:  The present data demonstrate that registration of locomotion followed by a
computerized evaluation of the movements is a simple non invasive quantitative method to define
disease severity and evaluate effectiveness of therapeutic agents in the CIA model.
Background
Rheumatoid arthritis (RA) is a systemic inflammatory
autoimmune disorder affecting approximately 1% of the
general population in the western countries. The disease is
characterized by a chronic poly-arthritis, synovial hyper-
plasia and erosive synovitis, progressive cartilage and
bone destruction and an accelerated loss of muscle mass,
also known as rheumatoid cachexia [1]. The average loss
of body cell mass (BCM) among patients with RA is
between 13 and 15% [2]. The BMC consists primarily of
muscle mass, visceral mass and immune cell mass. A
decrease in muscle mass can in part be explained by a
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decreased physical activity [3]. This decrease in physical
activity in RA patients is closely related to pain, character-
ized by hyperalgesia and spontaneous pain, mostly
caused and exacerbated by inflammatory mediators
(cytokines, prostaglandins) [4]. Other factors contribut-
ing to muscle protein wasting are increased levels of sys-
temic and local markers of inflammation (e.g. TNF-α, IL-
1β and IL-6) as well as increased levels of oxidative stress
[5].
The collagen-induced arthritis model (CIA) in mice is an
extensively studied RA model. It has been used to provide
insight into the underlying disease process of RA and is
frequently used to study the potential of new experimen-
tal therapies [6-8]. The development and severity of arthri-
tis in the CIA model is mostly detected by a semi-
quantitative clinical scoring system based on the severity
of arthritis in the peripheral joints [9]. Despite of being
the most widely used rodent model for RA, its use for
studying arthritic pain has been reported just recently
[10]. Moreover, only in small number of studies locomo-
tion was one of the readouts in the CIA models [11,12].
The present study evaluated locomotion (changes which
are at least partially pain induced), muscle mass (changes
might be inflammation and locomotion induced) and
clinical arthritis scores in the CIA model. The study aims
to determine the applicability of locomotion and muscle
mass changes as readout parameters in the CIA mouse
model and its relevance for intervention studies.
Methods
All experimental procedures using laboratory animals
were approved by an independent animal experiments
committee (DEC Consult, Bilthoven, The Netherlands).
Induction of CIA
Male DBA/1 mice (Taconic, Lille Skensved, Denmark),
aged 9 weeks at the start of the experiment were acclima-
tized in the animal housing facility starting two-weeks
prior to the start of the experiment. All animals were
housed in filter top cages and had free access to a water
and food. The food was applied as a daily fresh prepared
dough, this to simplify the food intake in the diseased
state. The mice were immunized by a subcutaneous injec-
tion of 100 μg native bovine collagen type II (Chondrex,
Zurich, Switzerland) emulsified in complete Freund Adju-
vant (CFA, Chondrex), at the base of the tail. An intra-
peritoneal booster of 100 μg of collagen type II in phos-
phate buffered saline (PBS) was given 21 days later. Mice
with a clear onset of arthritis at day 21 were excluded from
the experiment. After the booster 100% of the animals
developed arthritis within 9 days. To evaluate the effect of
pharmaceutical treatment on arthritis development and
locomotion one group of animals was treated with Meth-
otrexate, a frequently used disease-modifying anti-rheu-
matic drug (DMARD). Methotrexate (MTX, Emthexate PF,
Pharmachemie B.V., Haarlem, The Neterlands) was
injected three times a week (1 mg/kg, intra-peritoneal)
starting at the day of the collagen booster (day 21). Con-
trol mice were injected with PBS.
Assessment of CIA
After the booster the mice were examined three times a
week for visual appearance of arthritis. Clinical severity of
arthritis of the peripheral joints was graded on the level of
"macroscopic" inflammation on a scale of 0 to 4 [9]. 0, no
symptoms, 1 significant -, 2 moderate -, 3 marked – and 4
indicates maximal redness and swelling of the paw. The
scores of all paws were summarized to obtain the "arthri-
tis score", with a maximum of 16 for each mouse. Mice
with arthritis score of 12 or higher were for ethical reasons
excluded from the study. The mean arthritis score for each
group was calculated (mean ± SEM). Assessment of the
arthritis score was performed by two independent observ-
ers.
Assessment of locomotion
Twice, before the arthritis induction and at 9 days after the
collagen booster, mice were placed individually in an
acrylic movement box of 60 × 40 cm. Spontaneous,
exploratory locomotion of the animals was detected by a
camera which was positioned above the "movement"
boxes. The movements were registered for 5 minutes,
starting 2 minutes after the mice have been placed into the
Arthritis development, depicted as development after the  collagen booster (day 21) Figure 1
Arthritis development, depicted as development 
after the collagen booster (day 21). Values are 
expressed as the mean score ± SEM, n = 17.
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boxes. The movements were evaluated by a computerized
tracing system and image analyzer (EnthoVision 3.1,
Noldus, Wageningen, The Netherlands). The moved dis-
tance (in cm) for each group was calculated and averaged
(mean ± SEM). Changes in moving distance were calcu-
lated for each mouse as % of initial movement.
Detection of skeletal muscle mass
12 days after the collagen booster the animals were sacri-
ficed and the different skeletal muscles from the hind leg,
tibialis anterior (TA), gastrocnemius, soleus and exterior
digitorum longus (EDL) were dissected and weighted.
Statistical analysis
Averaged values are expressed as mean ± standard error of
the mean (SEM). Correlations were calculated using the
Pearson's linear regression model. The changes induced
by MTX were calculated by the independent-samples T-
Test.
Results
All results and conclusions are based on the data from ani-
mals with a maximum arthritis score of 12
Arthritis development
Arthritis development was detected in two independent
experiments. Twelve animals were included in each of the
test groups. At day 21, two animals from each test group
developed clinical arthritis, as detected by the arthritis
score, and were excluded from the rest of the experiment.
After the collagen booster (day 21) the arthritis score was
detected three times a week, animals with a score above 12
were sacrificed. The score of the different animals was
averaged; the arthritis development was depicted in figure
1.
Reproduction of the locomotion pattern before arthritis  development (A) and at 9 days after the collagen booster (B),  arthritis score 8 Figure 3
Reproduction of the locomotion pattern before 
arthritis development (A) and at 9 days after the col-
lagen booster (B), arthritis score 8. The mouse depicted 
corresponds to mouse which is marked with an arrow in fig-
ure 2B.
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Evaluation of locomotion in healthy and arthritis animals Figure 2
Evaluation of locomotion in healthy and arthritis ani-
mals. Locomotion was tested at 2 different time point (1 
and 2), with a 5 days interval, in a control group of animals 
(A, n = 42). At day 30, 9 days after the collagen booster loco-
motion was tested and changes were expressed as % changes 
of the initial locomotion against the arthritis score of the ani-
mal (B, n = 17).
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Assessment of locomotion
To investigate the reproducibility of the locomotion test,
locomotion was tested twice in a control group of ani-
mals, with an interval of 5 days. The results were depicted
in figure 2A. There is a significant correlation (Pearson r =
0.55, p = 0.0002) between the distance moved by the dif-
ferent animals at the first detection day and the distance
moved at the second detection day. The presence of "lazy"
and "active" animals indicates a need for individual calcu-
lation of movement changes. The average movement of
each mouse as detected in two measurements before the
start of arthritis induction was set at 100%. At day 30, 9
days after the collagen booster, locomotion was tested
again and changes in movement, as a percentage of the
initial movement, were calculated. The individual move-
ment changes were depicted against the individual arthri-
tis score at the detection day. There is a clear correlation
(Fig. 2B) between the decrease in locomotion and the
arthritis score (Pearson r = -78, p = 0.0001). The locomo-
tion pattern of the mouse in figure 2B which is marked
with an arrow was depicted in figure 3. Figure 3A shows
the locomotion pattern of the mouse before arthritis initi-
ation while figure 3B indicates the movement pattern after
arthritis development (arthritis score at the time of the
movement detection is 8). In order to test the relevance of
the locomotion parameter for testing therapeutics, the
effect of MTX treatment on the locomotion and the arthri-
tis score were detected. At nine days after the collagen
booster the MTX treatment resulted in a decreased arthri-
tis score of 48% (Fig. 4A) and an increase of locomotion
of 60% (Fig. 4B).
Muscle mass
After the mice were sacrificed at 12 days after the collagen
booster the different skeletal muscles form the hind legs
Correlation between muscle weight and locomotion (A) and  arthritis score (B) Figure 5
Correlation between muscle weight and locomotion 
(A) and arthritis score (B). The total weight of the differ-
ent skeletal muscles from the hind legs (tibialis anterior, gas-
trocnemius, soleus and exterior digitorum longus), weight 12 
days after the collagen booster, was depicted as a function of 
the % of locomotion after arthritis development (A, n = 20) 
and arthritis score (B, n = 20).

0 25 50 75 100 125 150
150
200
250
300
350
400
Locomotion % of control
T
o
t
a
l
 
m
u
s
c
l
e
 
w
e
i
g
h
t
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5
0
100
200
300
400
Arthritis score
T
o
t
a
l
 
m
u
s
c
l
e
 
w
e
i
g
h
t
A
B 
The effects of MTX treatment on the arthritis score and  locomotion, as detected nine days after the collagen booster,  were depicted in figure A and B respectively Figure 4
The effects of MTX treatment on the arthritis score 
and locomotion, as detected nine days after the colla-
gen booster, were depicted in figure A and B respec-
tively. Values are expressed as the mean ± SEM. Significant 
differences vs. the CIA condition were indicated by * (P < 
0.05).
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were dissected and weight. The changes in total weight of
the skeletal muscles of hind legs correlated significantly
(Pearson r = 0.53, p = 0.02) with the % of the initial loco-
motion as detected 9 days after the collagen booster (final'
movement study) (Fig. 5A) and with the arthritis score
(Fig. 5B, Pearson r = -0.49, p = 0.03). Comparison of the
individual muscles with locomotion or arthritis score did
not result in a significant correlation (data not shown).
MTX treatment, starting at the day of the collagen booster,
was able to significantly reduce the decrease in muscle
mass of the TA (Fig. 6A), the EDL (Fig. 6B) and gastrocne-
mius (Fig. 6C). The effect of MTX treatment on the soleus
was however not significant (Fig. 6D).
Discussion
The mouse model of CIA has been proven to be a useful
animal model for RA research because it shares many
immunological and pathological features with human RA
[13,14]. In the present study it was demonstrated that
there is a strong correlation between the macroscopic
arthritis score and locomotion. This locomotion test, by
which mice were placed in a new surrounding, strongly
correlates with the open field-tests performed to study
incidence and duration of certain behaviors [15]. Corre-
sponding results have been indicated by Inglis et al. stud-
ying hyperalgesia [10] and Millecamps et al. studying
behavior in a monoarthritic rat model [11]. However, in
these studies the correlation between locomotion and the
disease severity was not tested. To evaluate possible cor-
ruption of the locomotion values by habituation, the
effect of repeated measurements was tested. No differ-
ences in walking distance were detected in control mice
between different days of assaying (5 tests with an interval
of 3–7 days between each test, data not shown). The
repeated detection of locomotion in control mice did
reveal however, a mouse dependent initial locomotion.
These results stress the need for determination of the ini-
tial locomotion distance for each individual mouse. These
The effect of MTX treatment on the weight of the different skeletal muscles, tibialis anterior (A), exterior digitorum longus (B),  gastrocnemius (C), soleus (D) weight 12 days after the collagen booster Figure 6
The effect of MTX treatment on the weight of the different skeletal muscles, tibialis anterior (A), exterior dig-
itorum longus (B), gastrocnemius (C), soleus (D) weight 12 days after the collagen booster. Values are expressed 
as the mean ± SEM. Significant differences between the CIA condition and the MTX treated CIA condition were indicated by * 
(P < 0.05).

Control CIA CIA MTX
20
25
30
35
40
*
T
A
 
w
e
i
g
h
t
 
(
m
g
)
Control CIA CIA MTX
5
6
7
8
9
*
 
E
D
L
 
w
e
i
g
h
t
 
(
m
g
)
Control CIA CIA MTX
50
75
100
125
*
 
G
a
s
t
r
o
c
n
e
m
i
u
s
 
w
e
i
g
h
t
 
(
m
g
)
Control CIA CIA MTX
3
4
5
6
7
S
o
l
e
u
s
 
w
e
i
g
h
t
 
(
m
g
)
B
D 
A
C BMC Musculoskeletal Disorders 2009, 10:59 http://www.biomedcentral.com/1471-2474/10/59
Page 6 of 7
(page number not for citation purposes)
initial values were set by averaging the locomotion values
detected on two separate days before the start of the exper-
iment. The present data indicate that the quantitative
detection of locomotion strongly corresponds to clinical
changes as detected by the semi-quantitative detection of
disease severity. Also the total mass of the skeletal muscles
of the hind legs, as detected at the end of the experiment,
revealed to correlate to locomotion. These results suggest
a direct relation between movement and muscle mass.
However, movement is not the only factor effecting the
muscle mass in the CIA model. In contrast to the fact that
food intake by RA patients does not differ form the intake
by healthy people [16,17] a strong significant decreased
food intake by the CIA animals has been detected (data
not shown). Moreover, TNF-α which is believed to be a
central mediator of muscle wasting in RA exerts a power-
ful influence on muscle protein turnover resulting in a net
muscle protein wasting [18,19]. Increased serum levels of
TNF-α were detected in arthritic mice at the end of the
experiment (data not shown). Besides, direct effects of
pro-inflammatory cytokines on muscle metabolism, they
play a role in hyperalgesia resulting in decreased move-
ment. These interactions might indicate that muscle mass
might be a perfect biomarker for disease severity. How-
ever, the significant decrease in food intake hampers the
correlations between muscle mass loss and arthritis score
although a weak correlation between total muscle mass
and arthritis score could be detected.
A MTX intervention group was included to study more
detailed the applicability of locomotion detection for test-
ing treatment effectiveness of pharmaceuticals or other
disease interventions. MTX is the most frequently used
DMARD. Although the precise mechanisms in the treat-
ment of RA are not completely clear, MTX exerts a variety
of pharmacological actions resulting in suppression of the
disease activity and reduced joint damage [20,21]. In the
present CIA study the effects of MTX treatment on arthritis
score, locomotion and muscle mass were studied. In
agreement with previous publications [22] MTX inhibited
the arthritis development in the CIA model. Moreover,
treatment with MTX results in an increased locomotion.
The MTX data are in agreement with the finding that the
arthritis score displays an inverse correlation with loco-
motion. A protective effect of MTX treatment was also
detected on the muscle masse of the TA, the EDL and gas-
trocnemius. Although the correlation between muscle
masse and arthritis score was weak a clear modifying effect
by MTX could be detected in the separate muscles.
Conclusion
The present data indicate that movement detection by
camera followed by a computerized evaluation of the
locomotion is a simple non invasive quantitative method
to follow disease development or disease modulation by
interventions in the CIA model.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AH and JG contributed to the study design and the manu-
script preparation. AH contributed to the analysis and the
interpretation of the data. JH contributed to the study
design and the acquisition of the data. All authors read
and approved the final manuscript.
Acknowledgements
The authors wish to thank Diane Kegler and Nick van Wijk for technical 
assistance and locomotion data computing respectively. This research was 
performed within the framework of TI Pharma project T1-103.
References
1. Walsmith J, Roubenoff R: Cachexia in rheumatoid arthritis.  Int J
Cardiol 2002, 85(1):89-99.
2. Rall LC, Roubenoff R: Rheumatoid cachexia: metabolic abnor-
malities, mechanisms and interventions.  Rheumatology (Oxford)
2004, 43(10):1219-1223.
3. Mancuso CA, Rincon M, Sayles W, Paget SA: Comparison of
energy expenditure from lifestyle physical activities between
patients with rheumatoid arthritis and healthy controls.
Arthritis Rheum 2007, 57(4):672-678.
4. Schaible HG, Ebersberger A, Von Banchet GS: Mechanisms of pain
in arthritis.  Ann N Y Acad Sci 2002, 966:343-354.
5. Spate U, Schulze PC: Proinflammatory cytokines and skeletal
muscle.  Curr Opin Clin Nutr Metab Care 2004, 7(3):265-269.
6. Hegen M, Keith JC Jr, Collins M, Nickerson-Nutter CL: Utility of
animal models for identification of potential therapeutics for
Rheumatoid Arthritis.  Ann Rheum Dis 2007.
7. Cho YG, Cho ML, Min SY, Kim HY: Type II collagen autoimmu-
nity in a mouse model of human rheumatoid arthritis.
Autoimmun Rev 2007, 7(1):65-70.
8. Kannan K, Ortmann RA, Kimpel D: Animal models of rheuma-
toid arthritis and their relevance to human disease.  Pathophys-
iology 2005, 12(3):167-181.
9. Joosten LA, Helsen MM, Loo FA van de, Berg WB van den: Anticy-
tokine treatment of established type II collagen-induced
arthritis in DBA/1 mice. A comparative study using anti-TNF
alpha, anti-IL-1 alpha/beta, and IL-1Ra.  Arthritis Rheum 1996,
39(5):797-809.
10. Inglis JJ, Notley CA, Essex D, Wilson AW, Feldmann M, Anand P, Wil-
liams R: Collagen-induced arthritis as a model of hyperalgesia:
functional and cellular analysis of the analgesic actions of
tumor necrosis factor blockade.  Arthritis Rheum 2007,
56(12):4015-4023.
11. Millecamps M, Jourdan D, Leger S, Etienne M, Eschalier A, Ardid D:
Circadian pattern of spontaneous behavior in monarthritic
rats: a novel global approach to evaluation of chronic pain
and treatment effectiveness.  Arthritis Rheum 2005,
52(11):3470-3478.
12. Sasakawa T, Sasakawa Y, Ohkubo Y, Mutoh S: FK506 ameliorates
spontaneous locomotor activity in collagen-induced arthri-
tis: implication of distinct effect from suppression of inflam-
mation.  Int Immunopharmacol 2005, 5(3):503-510.
13. Williams RO: Collagen-induced arthritis in mice.  Methods Mol
Med 2007, 136:191-199.
14. Luross JA, Williams NA: The genetic and immunopathological
processes underlying collagen-induced arthritis.  Immunology
2001, 103(4):407-416.
15. Walsh RN, Cummins RA: The Open-Field Test: a critical
review.  Psychol Bull 1976, 83(3):482-504.
16. Gomez-Vaquero C, Nolla JM, Fiter J, Ramon JM, Concustell R, Val-
verde J, Roig-Escofet D: Nutritional status in patients with rheu-
matoid arthritis.  Joint Bone Spine 2001, 68(5):403-409.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Musculoskeletal Disorders 2009, 10:59 http://www.biomedcentral.com/1471-2474/10/59
Page 7 of 7
(page number not for citation purposes)
17. Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Daw-
son-Hughes B, Dinarello CA, Rosenberg IH: Rheumatoid
cachexia: cytokine-driven hypermetabolism accompanying
reduced body cell mass in chronic inflammation.  J Clin Invest
1994, 93(6):2379-2386.
18. Morley JE, Thomas DR, Wilson MM: Cachexia: pathophysiology
and clinical relevance.  Am J Clin Nutr 2006, 83(4):735-743.
19. Saini A, Al-Shanti N, Stewart CE: Waste management –
cytokines, growth factors and cachexia.  Cytokine Growth Factor
Rev 2006, 17(6):475-486.
20. Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, Wolfe
F: Evidence from clinical trials and long-term observational
studies that disease-modifying anti-rheumatic drugs slow
radiographic progression in rheumatoid arthritis: updating a
1983 review.  Rheumatology (Oxford) 2002, 41(12):1346-1356.
21. Wessels JA, Huizinga TW, Guchelaar HJ: Recent insights in the
pharmacological actions of methotrexate in the treatment
of rheumatoid arthritis.  Rheumatology (Oxford) 2008,
47(3):249-255.
22. Neurath MF, Hildner K, Becker C, Schlaak JF, Barbulescu K, Germann
T, Schmitt E, Schirmacher P, Haralambous S, Pasparakis M, et al.:
Methotrexate specifically modulates cytokine production by
T cells and macrophages in murine collagen-induced arthri-
tis (CIA): a mechanism for methotrexate-mediated immu-
nosuppression.  Clin Exp Immunol 1999, 115(1):42-55.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2474/10/59/pre
pub